0 CHECKOUT

Metastatic Ovarian Cancer - Pipeline Review, H1 2015

  • ID: 3169850
  • March 2015
  • 65 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aura Biosciences, Inc.
  • Eisai Co., Ltd.
  • Immune Design Corp.
  • Innate Pharma SA
  • VG Life Sciences, Inc.
  • MORE

Metastatic Ovarian Cancer - Pipeline Review, H1 2015

Summary

This, ‘Metastatic Ovarian Cancer - Pipeline Review, H1 2015’, provides an overview of the Metastatic Ovarian Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aura Biosciences, Inc.
  • Eisai Co., Ltd.
  • Immune Design Corp.
  • Innate Pharma SA
  • VG Life Sciences, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Metastatic Ovarian Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Ovarian Cancer - Overview
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis
Metastatic Ovarian Cancer - Therapeutics under Development by Companies
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Ovarian Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Metastatic Ovarian Cancer - Products under Development by Companies
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development
Aura Biosciences, Inc.
Eisai Co., Ltd.
Immune Design Corp.
Innate Pharma SA
Millennium Pharmaceuticals, Inc.
Northwest Biotherapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Metastatic Ovarian Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
antigen-presenting dendritic cells (living, autologous) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCVax-Direct - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Metastatic Ovarian Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-7449 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPH-2201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LV-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
orteronel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM-276001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metastatic Ovarian Cancer - Recent Pipeline Updates
Metastatic Ovarian Cancer - Dormant Projects
Metastatic Ovarian Cancer - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Metastatic Ovarian Cancer, H1 2015
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Metastatic Ovarian Cancer - Pipeline by Aura Biosciences, Inc., H1 2015
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2015
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H1 2015
Metastatic Ovarian Cancer - Pipeline by Innate Pharma SA, H1 2015
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2015
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Metastatic Ovarian Cancer - Dormant Projects, H1 2015
Metastatic Ovarian Cancer - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Metastatic Ovarian Cancer, H1 2015
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Aura Biosciences, Inc.
- Eisai Co., Ltd.
- Immune Design Corp.
- Innate Pharma SA
- Millennium Pharmaceuticals, Inc.
- Northwest Biotherapeutics, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- VG Life Sciences, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Almac Diagnostics Group
  • Pfizer Inc.
  • Astrazeneca PLC
  • Hologic Inc.
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb